EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"EQRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"EQRx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"EQRx","sponsor":"CM Life Sciences","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"EQRx","sponsor":"Abdul Latif Jameel Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"EQRx","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"EQRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"EQRx","sponsor":"Aurigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership With EQRX","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More than $1 Billion in Additional Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revolution Medicines Completes Acquisition of EQRx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by EQRx

    Menu

    EQRx

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              EQRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revolution Medicines Completes Acquisition of EQRx

              Details:

              Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.

              Lead Product(s): RMC-6236

              Therapeutic Area: Oncology Product Name: RMC-6236

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Revolution Medicines

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition November 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EQRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More than $1 Billion in Additional Capital

              Details:

              Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.

              Lead Product(s): RMC-6236

              Therapeutic Area: Oncology Product Name: RMC-6236

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Revolution Medicines

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition August 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EQRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership With EQRX

              Details:

              Under the terms of the collaboration agreement, Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Recipient: Aurigene

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EQRx

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

              Details:

              Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR.

              Lead Product(s): Aumolertinib

              Therapeutic Area: Oncology Product Name: EQ143

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EQRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets

              Details:

              The collaboration will combine Insilico's Pharma.AI platform to advance de novo small molecule design and generation with EQRx's clinical development and commercialization expertise.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Recipient: Insilico Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EQRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa

              Details:

              Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.

              Lead Product(s): Aumolertinib

              Therapeutic Area: Oncology Product Name: EQ143

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Abdul Latif Jameel Health

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EQRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III

              Details:

              Proceeds expand balance sheet to ~$2.0 billion and will be used for “new pharma” platforms. EQRx’s growing pipeline includes two pre-registrational oncology assets that have shown promising Phase 3 data (aumolertinib and sugemalimab), and other clinical-stage programs.

              Lead Product(s): Aumolertinib

              Therapeutic Area: Oncology Product Name: EQ143

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: CM Life Sciences

              Deal Size: $2,000.0 million Upfront Cash: $2,000.0 million

              Deal Type: Merger August 06, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EQRx

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer

              Details:

              GEMSTONE-301 study investigating sugemalimab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC without disease progression after either concurrent or sequential chemoradiotherapy.

              Lead Product(s): Sugemalimab

              Therapeutic Area: Oncology Product Name: CS1001

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: CStone Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EQRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing

              Details:

              Funding accelerates development of late-stage cancer therapies which includes sugemalimab, almonertinib, EQRx’s PD-1 antibody (formerly known as CS1003) and lerociclib, a CDK4/6 inhibitor.

              Lead Product(s): Sugemalimab

              Therapeutic Area: Oncology Product Name: CS1001

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $500.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing January 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY